T1	Participants 35 74	BRAF mutation in stage III colon cancer
T2	Participants 211 236	colorectal carcinogenesis
T3	Participants 448 484	patients with stage III colon cancer
T4	Participants 561 649	506 stage III colon cancer patients enrolled in a randomized adjuvant chemotherapy trial
T5	Participants 930 983	431 BRAF wild-type patients, 75 BRAF-mutated patients
